Regional Lymphadenitis Following Antileprosy Vaccine BCG with Killed Mycobacterium leprae

Lourduraj, R and Britto, J D and Ramanathan, V D and Gupte, M D (1997) Regional Lymphadenitis Following Antileprosy Vaccine BCG with Killed Mycobacterium leprae. International Journal of Leprosy and other Mycobacterial Diseases, 65 (1). pp. 12-19. ISSN 0148-916X

[thumbnail of 199703.pdf] PDF
199703.pdf - Published Version
Restricted to Registered users only

Download (50kB) | Request a copy


An effective antileprosy vaccine should protect against infection by Mycobacterium leprae or have therapeutic value against the disease. A number of potential vaccines based on either live BCG alone or with killed M. leprae (KML) or other killed mycobacteria such as ICRC, Mycobacterium w. and M. vaccae have been developed and have been claimed to be immunotherapeutic (2,4,18,20). Some of them are currently being evaluated for their immunoprophylactic efficacy against leprosy (6). The combination vaccine BCG plus KML was also tested for immunoprophylactic efficacy, and it was seen that there were 18% fewer cases from the vaccine group BCG plus KML than from the BCG group (3 ). But, no difference was seen between the BCG plus KML group and the BCG group among the general population in the Karonga Prevention Trial (11). Apart from being effective, a good vaccine needs to be safe with minimal side effects so that it is acceptable to the population using it. In Phase-II and extended Phase-II studies, three different population sets in Thiruthani taluk of Chengai- MGR District in Tamil Nadu, India, were tested during the period between August 1989 and October 1990 to ascertain the acceptability of the vaccines and the side effects, if any. In this communication, we are reporting on episodes of regional lymphadenitis in subjects who received BCG plus KML.

Item Type: Article
Subjects: Tuberculosis > Clinical Research
Divisions: Clinical Research
Depositing User: Dr. Rathinasabapati R
Date Deposited: 30 Sep 2013 09:37
Last Modified: 14 Mar 2016 04:42

Actions (login required)

View Item View Item